methylphenidate

Summary

Summary: A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE.

Top Publications

  1. pmc The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care
    Suzanne McCarthy
    School of Pharmacy, University College Cork, Cork, Ireland
    BMC Pediatr 12:78. 2012
  2. ncbi Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis
    Xavier Castells
    Psychiatry Department, Hospital Universitari Vall dHebron, Barcelona, Spain
    CNS Drugs 25:157-69. 2011
  3. ncbi Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task
    Katya Rubia
    Department of Child Psychiatry, Institute of Psychiatry, King s College, London, UK
    Neuropharmacology 57:640-52. 2009
  4. ncbi Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings
    W E Pelham
    Department of Psychology, State University of New York at Buffalo, Buffalo, New York, USA
    Pediatrics 107:E105. 2001
  5. ncbi Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review
    Dimitris Repantis
    Department of Psychiatry, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, 14050 Berlin, Germany
    Pharmacol Res 62:187-206. 2010
  6. ncbi Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder
    Nora D Volkow
    National Institute on Drug Abuse, 6001 Executive Blvd, Room 5274, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 64:932-40. 2007
  7. ncbi Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 47:21-31. 2008
  8. ncbi Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey
    Sean Esteban McCabe
    University of Michigan, Substance Abuse Research Center, Ann Arbor, MI 48105, USA
    Addiction 100:96-106. 2005
  9. pmc Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls
    D Tomasi
    National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
    Neuroimage 54:3101-10. 2011
  10. pmc Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naïve boys with attention-deficit hyperactivity disorder
    Katya Rubia
    Department of Child Psychiatry, Institute of Psychiatry, King s College London, London, UK
    Neuropsychopharmacology 36:1575-86. 2011

Detail Information

Publications333 found, 100 shown here

  1. pmc The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care
    Suzanne McCarthy
    School of Pharmacy, University College Cork, Cork, Ireland
    BMC Pediatr 12:78. 2012
    ..5-4%. Few data exist on the prescribing trends of the stimulants methylphenidate and dexamfetamine, and the non-stimulant atomoxetine in the UK...
  2. ncbi Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis
    Xavier Castells
    Psychiatry Department, Hospital Universitari Vall dHebron, Barcelona, Spain
    CNS Drugs 25:157-69. 2011
    The efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder (ADHD) shows wide between-study variability, which yields heterogeneous results in meta-analysis...
  3. ncbi Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task
    Katya Rubia
    Department of Child Psychiatry, Institute of Psychiatry, King s College, London, UK
    Neuropharmacology 57:640-52. 2009
    ..ADHD) have deficits in motivation and attention that can be ameliorated with the indirect dopamine agonist Methylphenidate (MPH)...
  4. ncbi Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings
    W E Pelham
    Department of Psychology, State University of New York at Buffalo, Buffalo, New York, USA
    Pediatrics 107:E105. 2001
    b>Methylphenidate (MPH), the most commonly prescribed drug for attention-deficit/hyperactivity disorder (ADHD), has a short half-life, which necessitates multiple daily doses...
  5. ncbi Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review
    Dimitris Repantis
    Department of Psychiatry, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, 14050 Berlin, Germany
    Pharmacol Res 62:187-206. 2010
    ..Of known interventions, psychopharmacology provides readily available options, such as methylphenidate and modafinil. Both drugs are presumed to be in widespread use as cognitive enhancers for non-medical reasons...
  6. ncbi Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder
    Nora D Volkow
    National Institute on Drug Abuse, 6001 Executive Blvd, Room 5274, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 64:932-40. 2007
    ..There is considerable evidence that brain dopamine is involved in ADHD, but it is unclear whether dopamine activity is enhanced or depressed...
  7. ncbi Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 47:21-31. 2008
    ..The purpose of this systematic review of the literature is to evaluate the extent and characteristics of stimulant misuse and diversion in attention-deficit/hyperactivity disorder (ADHD) and non-ADHD individuals...
  8. ncbi Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey
    Sean Esteban McCabe
    University of Michigan, Substance Abuse Research Center, Ann Arbor, MI 48105, USA
    Addiction 100:96-106. 2005
    ..To examine the prevalence rates and correlates of non-medical use of prescription stimulants (Ritalin, Dexedrine or Adderall) among US college students in terms of student and college characteristics...
  9. pmc Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls
    D Tomasi
    National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
    Neuroimage 54:3101-10. 2011
    b>Methylphenidate (MPH) is a stimulant drug that amplifies dopamineric and noradrenergic signaling in the brain, which is believed to underlie its cognition enhancing effects...
  10. pmc Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naïve boys with attention-deficit hyperactivity disorder
    Katya Rubia
    Department of Child Psychiatry, Institute of Psychiatry, King s College London, London, UK
    Neuropsychopharmacology 36:1575-86. 2011
    ..have deficits in interference inhibition, which can be improved with the indirect catecholamine agonist methylphenidate (MPH)...
  11. ncbi Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
    N D Volkow
    Medical Department, Brookhaven National Laboratory, Upton, New York 11973, USA
    Nature 386:830-3. 1997
    ..emission tomography (PET) to compare the responses of cocaine addicts and normal controls to intravenous methylphenidate, a drug that, like cocaine, causes an increase in synaptic dopamine...
  12. pmc Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration
    Christian J Teter
    School of Pharmacy, Northeastern University, Boston, Massachusetts, USA
    Pharmacotherapy 26:1501-10. 2006
    ..To explore the illicit use of specific prescription stimulants among college students and add to our understanding of reasons (motives) and routes of administration associated with illicit use of these drugs...
  13. ncbi Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory
    Philip L Clatworthy
    Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge CB2 3EB, United Kingdom
    J Neurosci 29:4690-6. 2009
    Previous data suggest that methylphenidate can have variable effects on different cognitive tasks both within and between individuals...
  14. ncbi Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate
    N D Volkow
    Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    Am J Psychiatry 155:1325-31. 1998
    The therapeutic effects of methylphenidate in the treatment of attention deficit disorder have been attributed to its ability to increase the synaptic concentration of dopamine by blocking the dopamine transporters...
  15. pmc Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood flow in healthy volunteers at rest: a multi-class pattern recognition approach
    Andre F Marquand
    Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, King s College London, UK
    Neuroimage 60:1015-24. 2012
    The stimulant drug methylphenidate (MPH) and the non-stimulant drug atomoxetine (ATX) are both widely used for the treatment of attention deficit/hyperactivity disorder (ADHD), but their differential effects on human brain function are ..
  16. pmc Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder
    Nora D Volkow
    National Institute on Drug Abuse, Bethesda, Maryland 20892, USA
    J Neurosci 32:841-9. 2012
    Stimulant medications, such as methylphenidate, which are effective treatments for attention deficit hyperactivity disorder (ADHD), enhance brain dopamine signaling...
  17. ncbi Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition
    Astrid M Pauls
    Department of Neuroimaging, Institute of Psychiatry, King s College London, United Kingdom
    Biol Psychiatry 72:142-9. 2012
    b>Methylphenidate improves motor response inhibition, typically assessed with the stop-signal task. The exact underlying mechanism for this, however, remains unknown...
  18. ncbi Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder
    James C Ermer
    Clinical Pharmacology and Pharmacokinetics, Shire Development Inc, Wayne, Pennsylvania, USA
    CNS Drugs 24:1009-25. 2010
    b>Methylphenidate- and amfetamine-based stimulants are first-line pharmacotherapies for attention-deficit hyperactivity disorder, a common neurobehavioural disorder in children and adults...
  19. ncbi Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain
    N D Volkow
    Departments of Medical and Chemistry, Brookhaven National Laboratory, Upton, New York 11973, USA
    J Neurosci 21:RC121. 2001
    b>Methylphenidate (Ritalin) is the most commonly prescribed psychoactive drug in children for the treatment of attention deficit hyperactivity disorder (ADHD), yet the mechanisms responsible for its therapeutic effects are poorly ..
  20. ncbi Differential effects of methylphenidate on problem solving in adults with ADHD
    Lara Tucha
    Department of Psychology, Faculty of Behavioural and Social Sciences, University of Groningen, Grote Kruisstraat 2 1, 9712 TS Groningen, Netherlands
    J Atten Disord 15:161-73. 2011
    ..Two studies were performed to assess both divergent and convergent thinking in adults with ADHD...
  21. pmc Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder
    Tanya E Froehlich
    University of Cincinnati College of Medicine and Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Am Acad Child Adolesc Psychiatry 50:1129-1139.e2. 2011
    ..This study examined the role of four catecholamine-related candidate genes in moderating methylphenidate (MPH) dose-response.
  22. ncbi Short-term cardiovascular effects of methylphenidate and adderall
    R L Findling
    Department of Psychiatry and Pediatrics, University Hospitals of Cleveland, Case Western Reserve University, OH 44106-5080, USA
    J Am Acad Child Adolesc Psychiatry 40:525-9. 2001
    ..METHOD: One hundred thirty-seven patients were treated with either methylphenidate (MPH) or ADL...
  23. ncbi The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry
    T W Robbins
    Department of Experimental Psychology, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK
    Psychopharmacology (Berl) 163:362-80. 2002
    ..The developmental history and application of the 5-choice serial reaction time task (5CSRTT) for measuring effects of drugs and other manipulations on attentional performance (and stimulus control) in rats is reviewed...
  24. ncbi Attention deficit hyperactivity disorder in adults
    Michael Rösler
    Neurozentrum, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    World J Biol Psychiatry 11:684-98. 2010
    ..To examine available literature regarding attention deficit hyperactivity disorder (ADHD) in adults...
  25. ncbi Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database
    Suzanne McCarthy
    Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of London and the Institute of Child Health, University College London, London, UK
    Drug Saf 32:1089-96. 2009
    ....
  26. ncbi A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder
    Mark A Stein
    Department of Psychiatry, University of Chicago, Chicago, Illinois 60637, USA
    Pediatrics 112:e404. 2003
    OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD)...
  27. pmc Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder
    Philip Shaw
    Child Psychiatry Branch, Bldg 10, Center Dr, NIMH, Bethesda, MD 20892, USA
    Am J Psychiatry 166:58-63. 2009
    ..The authors sought to determine prospectively whether psychostimulant treatment for attention deficit hyperactivity disorder (ADHD) was associated with differences in the development of the cerebral cortex during adolescence...
  28. ncbi Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate
    Elizabeth B Liddle
    University of Nottingham, Nottingham, UK
    J Child Psychol Psychiatry 52:761-71. 2011
    ..We also hypothesised that methylphenidate, an indirect dopamine agonist, would tend to normalise abnormal patterns of DMN deactivation.
  29. ncbi Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults
    Suzanne McCarthy
    Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London and Institute of Child Health, University College London, UK
    Br J Psychiatry 194:273-7. 2009
    ..Symptoms of attention-deficit hyperactivity disorder (ADHD) are known to persist into adulthood in the majority of cases...
  30. ncbi Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity
    Mitul A Mehta
    University of Cambridge, Department of Psychiatry, UK
    J Child Psychol Psychiatry 45:293-305. 2004
    ..Clear delineation of the effects of methylphenidate upon such cognitive functions in AD/HD would enhance understanding of the effects of drug treatment.
  31. ncbi Review of medication adherence in children and adults with ADHD
    Lisa D Adler
    Cornell University, Ithaca, NY, USA
    Postgrad Med 122:184-91. 2010
    ..To review the literature on the prevalence, potential causes, and consequences of medication nonadherence in adult attention-deficit/hyperactivity disorder (ADHD)...
  32. ncbi Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone
    Neil E Paterson
    Behavioral Pharmacology, PsychoGenics, Inc, Tarrytown, NY 10591, USA
    Neurosci Res 69:41-50. 2011
    ..5-2.0 mg/kg), the mixed DA/NE reuptake inhibitor methylphenidate (0.1-2.0 mg/kg), the catecholamine releaser D-amphetamine (0.1-1...
  33. ncbi A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder
    Margaret Steele
    Department of Psychiatry, Pediatrics and Family Medicine, University of Western Ontario, London, ON
    Can J Clin Pharmacol 13:e50-62. 2006
    The thrice daily dosing regimen of immediate release methylphenidate (IR-MPH) for Attention Deficit/Hyperactivity Disorder (ADHD) requires in-school dosing, leading to issues surrounding dispensing and storage of controlled substances by ..
  34. ncbi Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study
    Umesh Jain
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    J Clin Psychiatry 68:268-77. 2007
    To evaluate the efficacy and safety of a new biphasic multilayer-release (MLR) methylphenidate formulation in a double-blind, placebo-controlled crossover study of adults with attention-deficit/hyperactivity disorder (ADHD).
  35. ncbi Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults
    John S Markowitz
    Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 0742, USA
    Clin Pharmacokinet 42:393-401. 2003
    To compare the rate and extent of absorption of DL-threo-methylphenidate (MPH) from two modified-release MPH formulations at their respective recommended starting doses in healthy adult volunteers.
  36. ncbi Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder
    Normand J Carrey
    Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada
    J Child Adolesc Psychopharmacol 17:11-7. 2007
    ..We used short echo proton magnetic resonance spectroscopy (1H-MRS) to examine glutamate in the prefrontal cortex, left striatum, and, as a control area, the occipital lobe...
  37. ncbi Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder
    C C E Overtoom
    Department of Psychopharmacology, Faculty of Pharmacy, Utrecht University, P O BOX 80082, 3508 TB, Utrecht, The Netherlands
    Behav Brain Res 145:7-15. 2003
    The objective of this study was to investigate the effects of methylphenidate (MPH) on attention and inhibition in children with Attention Deficit Hyperactivity Disorder (ADHD) and to establish what the relative contributions of the ..
  38. pmc Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence
    Suzanne McCarthy
    School of Pharmacy, University College Cork, Cork, Ireland
    BMC Psychiatry 12:219. 2012
    ....
  39. ncbi The use of methylphenidate among students: the future of enhancement?
    Simon M Outram
    Novel Tech Ethics, Dalhousie University, 1234 LeMarchant Street, Halifax NS B3H 3P7, Canada
    J Med Ethics 36:198-202. 2010
    ..following paper seeks to examine the foundations of this cognitive enhancement debate using the example of methylphenidate use among college students...
  40. pmc Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study
    C J Vaidya
    Department of Psychology, Stanford University, Stanford, CA 94305
    Proc Natl Acad Sci U S A 95:14494-9. 1998
    ..Hyperactivity Disorder (ADHD) and healthy controls in their frontal-striatal function and its modulation by methylphenidate during response inhibition. Children performed two go/no-go tasks with and without drug...
  41. ncbi Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis
    Philip L Hazell
    Discipline of Psychological Medicine, Concord Clinical School, The University of Sydney, Australia
    J Atten Disord 15:674-83. 2011
    Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal...
  42. pmc Modulation of social influence by methylphenidate
    Daniel K Campbell-Meiklejohn
    Center for Functionally Integrative Neuroscience, Aarhus University, Aarhus, Denmark
    Neuropsychopharmacology 37:1517-25. 2012
    ..b>Methylphenidate (MPH) is an indirect dopamine and noradrenalin agonist, commonly used for the treatment of attention-deficit ..
  43. pmc An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety
    Manfred Dopfner
    Department of Child and Adolescent Psychiatry, University of Cologne, Cologne, Germany
    Eur Child Adolesc Psychiatry 20:S243-55. 2011
    ADHD affects over 5% of children worldwide. It is typically treated with stimulant medications, and methylphenidate (MPH) is the most commonly prescribed...
  44. ncbi Safety of therapeutic methylphenidate in adults: a systematic review of the evidence
    J Godfrey
    Westhaven and Portland CMHT, Westhaven, Weymouth, Dorset, UK
    J Psychopharmacol 23:194-205. 2009
    Attention deficit hyperactivity disorder (ADHD) often persists into adulthood. Stimulant drugs, including methylphenidate, have showed efficacy in trials for ADHD in adults...
  45. pmc Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis
    Raveen Hanwella
    Department of Psychological Medicine, Faculty of Medicine, University of Colombo, Sri Lanka
    BMC Psychiatry 11:176. 2011
    Psychostimulants and non stimulants are effective in the treatment of ADHD. Efficacy of both methylphenidate and atomoxetine has been established in placebo controlled trials...
  46. ncbi Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review
    S H Kollins
    Department of Psychiatry, Duke University Medical Center, Box 3431, Durham, NC 27710, USA
    Pharmacol Biochem Behav 68:611-27. 2001
    b>Methylphenidate (MPH) is widely used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults...
  47. pmc Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function
    Roxann C Harvey
    Department of Psychology, Boston University, Boston, MA 02215, USA
    Neuropsychopharmacology 36:837-47. 2011
    ..Initially, 1.5 mg/kg oral methylphenidate or vehicle was administered between postnatal days 28 and 55, and acquisition of visual discrimination ..
  48. ncbi Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany
    Christina Lindemann
    Bremen Institute for Prevention Research and Social Medicine, Bremen, Germany
    J Child Adolesc Psychopharmacol 22:307-14. 2012
    ..The purpose of this study was to estimate the prevalence and incidence of new diagnoses of attention-deficit/hyperactivity disorder (ADHD) and assess drug treatment of ADHD in the 3-17 year age group in Germany...
  49. ncbi Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder
    Caroline Davis
    Department of Kinesiology and Health Sciences, York University, Toronto, ON, Canada
    Neuropsychopharmacology 32:2199-206. 2007
    ..The current study used a double blind, crossover (methylphenidate vs placebo) design to assess DAT1 genotype differences on appetite ratings to a snack-food cue in subjects ..
  50. ncbi Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults
    Nirit Agay
    Israel Institute of Technology, Haifa, 32000, Israel
    Psychopharmacology (Berl) 210:511-9. 2010
    The effect of a single dose of methylphenidate (MPH) on cognitive measures and decision-making processes was assessed in a sample of adults with ADHD and in a control sample.
  51. ncbi ADHD in children, adolescents, and adults
    Sreenivas Katragadda
    Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, NH 03766, USA
    Prim Care 34:317-41; abstract viii. 2007
    ..The primary care physician should be able to screen, diagnose, educate, and initiate medication management in patients with uncomplicated ADHD...
  52. pmc Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate
    J K Buitelaar
    Department of Cognitive Neuroscience, University Medical Centre, St Radboud and Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, The Netherlands
    Psychol Med 42:195-204. 2012
    ..Daily functioning was assessed as part of an open-label extension, and associations with symptom scores were evaluated...
  53. ncbi Methylphenidate and risk of serious cardiovascular events in adults
    Hedi Schelleman
    Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
    Am J Psychiatry 169:178-85. 2012
    The authors sought to determine whether use of methylphenidate in adults is associated with elevated rates of serious cardiovascular events compared with rates in nonusers.
  54. ncbi Sex differences in attentional performance and their modulation by methylphenidate in children with attention-deficit/hyperactivity disorder
    Thomas Gunther
    Child Neuropsychology Section, Department of Child and Adolescent Psychiatry, University Hospital of the RWTH Aachen, Aachen, Germany
    J Child Adolesc Psychopharmacol 20:179-86. 2010
    ..known about neuropsychological differences between boys and girls with attention-deficit/hyperactivity disorder (ADHD) and whether there are sex-specific differences in the modulation of attentional performance by methylphenidate (MPH).
  55. ncbi Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice
    Ken Koda
    Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565 0871, Japan
    J Neurochem 114:259-70. 2010
    Acute administration of atomoxetine and methylphenidate, attention-deficit/hyperactivity disorder (ADHD) drugs, activates catecholaminergic systems in rat brain, but the effects of their chronic administration are not known...
  56. ncbi Methylphenidate HCl: therapy for attention deficit hyperactivity disorder
    Philip K Capp
    George Washington University, Department of Neurology, Children s National Medical Center, School of Medicine, Washington DC, USA
    Expert Rev Neurother 5:325-31. 2005
    b>Methylphenidate is a first-line therapy for attention deficit hyperactivity disorder, the most prevalent neuropsychiatric disorder of childhood...
  57. ncbi Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors
    N D Volkow
    Brookhaven National Laboratory, Upton, New York, USA
    J Pharmacol Exp Ther 291:409-15. 1999
    ..v. methylphenidate in 14 healthy controls...
  58. ncbi A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder
    S R Pliszka
    Division of Child and Adolescent Psychiatry, University of Texas Health Science Center, San Antonio UTHSCSA 78284 7792, USA
    J Am Acad Child Adolesc Psychiatry 39:619-26. 2000
    While Adderall has been available for the treatment of attention-deficit/hyperactivity disorder (ADHD) for several years, there are few controlled studies comparing it to methylphenidate.
  59. ncbi Methylphenidate-induced improvements of various measures of attention in adults with attention deficit hyperactivity disorder
    O Tucha
    Department of Experimental Psychology, University of Regensburg, Regensburg, Germany
    J Neural Transm 113:1575-92. 2006
    The present study examined the effect of the stimulant medication methylphenidate (MPH) on attentional functioning of adults with ADHD...
  60. ncbi Methylphenidate improves deficient error evaluation in children with ADHD: an event-related brain potential study
    Lisa M Jonkman
    Faculty of Psychology, Department of Cognitive Neuroscience, Maastricht University, Maastricht, The Netherlands
    Biol Psychol 76:217-29. 2007
    ..Furthermore, effects of methylphenidate were investigated in ADHD children in a second study...
  61. ncbi Differential effects of psychomotor stimulants on attentional performance in rats: nicotine, amphetamine, caffeine and methylphenidate
    L Bizarro
    Section of Behavioural Pharmacology, Institute of Psychiatry P049, King s College London, UK
    Behav Pharmacol 15:195-206. 2004
    ..This study compared the effects of nicotine, amphetamine, caffeine and methylphenidate on performance in the 5-CSRTT and determined whether presenting stimuli at unpredictable times by using ..
  62. pmc Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder
    Michael Cannon
    Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio, USA
    J Child Adolesc Psychopharmacol 19:511-7. 2009
    The aim of this study was to determine the effect on family quality of life (QOL) of clonidine (CLON) and methylphenidate (MPH), used alone and in combination, in treating attention-deficit/hyperactivity disorder (ADHD).
  63. ncbi A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder
    Laurence L Greenhill
    New York State Psychiatric Institute, New York, New York 10032, USA
    Pediatrics 109:E39. 2002
    To compare the efficacy, safety, and tolerability of once-daily administration of modified-release methylphenidate (MPH MR) with placebo in children with attention-deficit/hyperactivity disorder (ADHD).
  64. ncbi Juvenile administration of methylphenidate attenuates adult hippocampal neurogenesis
    Diane C Lagace
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Biol Psychiatry 60:1121-30. 2006
    The neural consequences of early-life exposure to methylphenidate (MPH; Ritalin) are of great interest given the widespread, and sometimes inappropriate, use in children...
  65. pmc Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress
    James Swanson
    Department of Pediatrics, University of California, Irvine, CA, USA
    Neuropsychopharmacology 36:207-26. 2011
    ..This treatment is well grounded on controlled studies showing efficacy of low oral doses of methylphenidate and amphetamine in reducing the behavioral symptoms of the disorder as reported by parents and teachers, both ..
  66. ncbi The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety
    D J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham NG1 1GF, UK
    Neuropharmacology 57:608-18. 2009
    ..classes: psychostimulant releasing agents, eg d-amphetamine; psychostimulant reuptake inhibitors, eg dl-threo-methylphenidate (dl-MPH), and non-stimulant reuptake inhibitors, eg atomoxetine...
  67. pmc Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers
    Andre F Marquand
    Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, King s College London, London, UK
    Neuropsychopharmacology 36:1237-47. 2011
    ..The stimulant drug methylphenidate (MPH) and the non-stimulant drug atomoxetine (ATX) are both widely used for ADHD treatment, but their ..
  68. ncbi Neurochemical enhancement of conscious error awareness
    Robert Hester
    Department of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia
    J Neurosci 32:2619-27. 2012
    ..We conducted a randomized, double-blind, placebo-controlled, cross-over design of the influence of methylphenidate, atomoxetine, and citalopram on error awareness in 27 healthy participants...
  69. ncbi Phenotypic characterization of a new Grin1 mutant mouse generated by ENU mutagenesis
    Tamio Furuse
    Technology and Development Team for Mouse Phenotype Analysis Japan Mouse Clinic, RIKEN BioResource Center, 3 1 1 Koyadai, Tsukuba, Ibaraki 305 0074, Japan
    Eur J Neurosci 31:1281-91. 2010
    ..The results of immunohistochemical and biochemical analyses suggested that impaired interaction between the glutamatergic pathway and dopaminergic pathway may underlie the behavioral phenotypes of the Grin1(Rgsc174) mutant...
  70. ncbi What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD)
    Claire Advokat
    Department of Psychology, Louisiana State University, 215 Audubon Hall, Baton Rouge, LA 70803, USA
    Neurosci Biobehav Rev 34:1256-66. 2010
    The relevant literature concerning cognitive effects of amphetamine and methylphenidate, was reviewed, with an emphasis on research conducted in adults diagnosed with attention-deficit/hyperactivity disorder...
  71. ncbi Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test
    Rachel Navarra
    Discovery Neuroscience, Wyeth Research, 500 Arcola Road, PA 19426 USA
    Prog Neuropsychopharmacol Biol Psychiatry 32:34-41. 2008
    ..first non-stimulant based drug approved for Attention Deficit Hyperactivity Disorder (ADHD) and has replaced methylphenidate (Ritalin) as the first line in pharmacotherapy for the treatment of ADHD...
  72. ncbi Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 28:S46-53. 2008
    Stimulants are part of the standard-of-care treatment for attention-deficit/hyperactivity disorder (ADHD). Methylphenidate, with a history of use spanning approximately 5 decades, is a first-line stimulant treatment for ADHD...
  73. ncbi Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity
    Julie B Schweitzer
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Biol Psychiatry 56:597-606. 2004
    We examined the effect of prolonged methylphenidate (MPH) treatment on the functional neuroanatomy of executive functioning in adult men with attention-deficit/hyperactivity disorder (ADHD).
  74. pmc Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate
    Katya Rubia
    Department of Child Psychiatry MRC Center for Social, Genetic and Developmental Psychiatry SGDP, Institute of Psychiatry, 16 De Crespigny Park, London, UK
    Philos Trans R Soc Lond B Biol Sci 364:1919-31. 2009
    ..dysfunctions in ADHD children during time discrimination with the dopamine agonist and treatment of choice, methylphenidate. This review together with the new empirical findings demonstrates that neurocognitive dysfunctions in ..
  75. ncbi A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats
    Steve Teo
    Pharmacokinetics and Toxicology, Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA
    Toxicology 179:183-96. 2002
    D-methylphenidate is an enantiomer of D,L-methylphenidate and was developed as an improved treatment for attention deficit hyperactivity disorder in children...
  76. ncbi Dimensional analysis of ADHD subtypes in rats
    Candice Blondeau
    Hôpital Charles Perrens, Laboratoire de Neuropsychobiologie des Desadaptations, Université Victor Segalen Bordeaux 2 CNRS UMR 554 1, Bordeaux, France
    Biol Psychiatry 61:1340-50. 2007
    ..The nature of the biological dysfunction sustaining each subtype (common or distinct) is unknown, and animal models encompassing different subtypes are needed...
  77. ncbi Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task
    George Bush
    Departments of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    Arch Gen Psychiatry 65:102-14. 2008
    ..Stimulant medications are effective treatments for ADHD, but their neural effects have not been fully characterized...
  78. ncbi ADHD- and medication-related brain activation effects in concordantly affected parent-child dyads with ADHD
    Jeffery N Epstein
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Child Psychol Psychiatry 48:899-913. 2007
    ..Our objective was to examine functional brain abnormalities among youths and adults with ADHD and to examine the relations between these neurobiological abnormalities and response to stimulant medication...
  79. pmc Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo
    Jonas Hannestad
    Department of Psychiatry, Yale PET Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 68:854-60. 2010
    ..The mechanism of action of methylphenidate, the most common treatment for attention deficit hyperactivity disorder, is unclear...
  80. ncbi Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder
    Gary Stiefel
    St Mary s Hospital, London, UK
    Drug Saf 33:821-42. 2010
    ..Drugs such as methylphenidate, amphetamines and atomoxetine are frequently prescribed as part of management...
  81. ncbi Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour
    R D Rogers
    Departments of Experimental Psychology and Psychiatry, University of Cambridge, Cambridge, UK
    Psychopharmacology (Berl) 146:482-91. 1999
    ..However, little research has addressed the specific cognitive consequences of changed monoaminergic function that might contribute to the production of impulsive behaviour...
  82. pmc Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics
    Tanya E Froehlich
    Division of Developmental and Behavioral Pediatrics, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    CNS Drugs 24:99-117. 2010
    ..ADHD pharmacogenetic investigative efforts to date, which have primarily focused on short-term response to methylphenidate and largely been limited by modest sample sizes...
  83. ncbi A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder
    Michael Rösler
    Neurocenter, Saarland University Hospital, 66421, Homburg Saar, Germany
    Eur Arch Psychiatry Clin Neurosci 259:120-9. 2009
    ..Although stimulants and methylphenidate in particular are a common off-label treatment for adult patients with ADHD in European countries, little is ..
  84. ncbi New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD
    D J Heal
    RenaSci Consultancy Limited, BioCity, Nottingham NG1 1GF, UK
    Pharmacol Biochem Behav 90:184-97. 2008
    ..Furthermore, experiments performed with the enantiomers of amphetamine and threo-methylphenidate demonstrate that pharmacodynamic effects of drugs reported from experiments in outbred rat strains, e.g...
  85. ncbi Recovery in pediatric brain injury: is psychostimulant medication beneficial?
    S E Williams
    Department of Psychiatry, Stanford University Medical Center, Stanford, California 94305, USA
    J Head Trauma Rehabil 13:73-81. 1998
    To assess the effects of methylphenidate on attention, memory, behavior, processing speed, and psychomotor skills of children with closed head injuries.
  86. ncbi [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor
    S Breit
    Department of Neurology, University of Tubingen, Tubingen, Germany
    J Neural Transm 113:187-93. 2006
    ..essential tremor and 10 healthy controls were studied with the dopamine transporter ligand [(11)C]d-threo-methylphenidate ([(11)C]dMP) and positron emission tomography (PET) to assess dopamine terminal loss in relation to disease ..
  87. pmc A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents
    Cesar Soutullo
    Child and Adolescent Psychiatry Unit, Department of Psychiatry and Medical Psychology, University of Navarra Clinic, Pio XII, S N, 31008 Pamplona, Spain
    CNS Drugs 27:743-51. 2013
    There are limited head-to-head data comparing the efficacy of long-acting amfetamine- and methylphenidate-based psychostimulants as treatments for individuals with attention-deficit hyperactivity disorder (ADHD)...
  88. ncbi Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder
    David Pierce
    Shire Pharmaceutical Development Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hampshire, UK
    J Clin Psychopharmacol 30:554-64. 2010
    ..multicenter, open-label, randomized study to determine single- and multiple-dose pharmacokinetics of d,l-methylphenidate (MPH) after MPH transdermal system (MTS) and osmotic-release oral system MPH (OROS MPH) dosing in children (6-..
  89. ncbi Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials
    Xavier Castells
    Department of Medical Sciences, TransLab Research Group, Universitat de Girona, Girona, Spain
    Eur J Clin Pharmacol 69:347-56. 2013
    Attention deficit hyperactivity disorder (ADHD) in adulthood is increasingly diagnosed and treated. Methylphenidate is frequently advocated as a first-line pharmacological treatment.
  90. ncbi Abuse and dependence liability analysis of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder (ADHD): what have we learned?
    Ike dela Peña
    Department of Pharmacy, Sahmyook University, 26 21 Kongreung 2 dong, Hwarangro 815, Nowon Gu, Seoul, 139 742, Korea
    Arch Pharm Res 36:400-10. 2013
    b>Methylphenidate is the most prescribed stimulant medication for attention-deficit/hyperactivity disorder (ADHD)...
  91. pmc Conditioned place preference induced by social play behavior: parametrics, extinction, reinstatement and disruption by methylphenidate
    Viviana Trezza
    Rudolf Magnus Institute of Neuroscience, Dept of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
    Eur Neuropsychopharmacol 19:659-69. 2009
    ..Treatment with methylphenidate, which disrupts social play behavior in adolescent rats, but not social exploratory behavior, prevented the ..
  92. ncbi A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy
    Jerome M Butler
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Int J Radiat Oncol Biol Phys 69:1496-501. 2007
    ..We assessed the effect of prophylactic d-threo-methylphenidate HCl (d-MPH), a central nervous system (CNS) stimulant on QOL and cognitive function in patients undergoing RT.
  93. ncbi Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study
    Lenard A Adler
    NYU School of Medicine, New York VA Harbor Healthcare System, New York, NY 10016, USA
    J Clin Psychopharmacol 29:239-47. 2009
    To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the management of attention-deficit/hyperactivity disorder (ADHD) in adults.
  94. ncbi Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination
    Anna Smith
    Department of Child Psychiatry, Institute of Psychiatry, King s College London, United Kingdom Electronic address
    Biol Psychiatry 74:615-22. 2013
    The catecholamine agonists methylphenidate and atomoxetine effectively treat attention-deficit/hyperactivity disorder (ADHD). Furthermore, dopamine agonists have shown to improve time estimation in ADHD, a core cognitive deficit...
  95. ncbi Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability
    M C Meyer
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee, Memphis 38163, USA
    Pharm Res 17:381-4. 2000
    To determine the relative bioavailability of two marketed, immediate-release methylphenidate tablets...
  96. pmc Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice
    Shankar Sadasivan
    Department of Developmental Neurobiology, St Jude Children s Research Hospital, Memphis, Tennessee, United States of America
    PLoS ONE 7:e33693. 2012
    b>Methylphenidate (MPH) is a psychostimulant that exerts its pharmacological effects via preferential blockade of the dopamine transporter (DAT) and the norepinephrine transporter (NET), resulting in increased monoamine levels in the ..
  97. ncbi One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder
    Anna Didoni
    Department of Public Health and of the Laboratory for Mother and Child Health, Mario Negri Pharmacological Research Institute, Via Giuseppe La Masa 19, 20156 Milan, Italy
    Eur J Clin Pharmacol 67:1061-7. 2011
    To delineate the safety and tolerability profile of methylphenidate and atomoxetine in children and adolescents with attention deficit hyperactivity disorder (ADHD) monitored for more than 1 year.
  98. ncbi Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans
    Dolly A Parasrampuria
    McNeil Pediatrics, Division of McNeil PPC, 420 Delaware Drive, Fort Washington, PA 19034, USA
    J Clin Pharmacol 47:1476-88. 2007
    ..stimulant use, to evaluate the abuse-related subjective effects of oral osmotic-controlled extended-release methylphenidate with comparable doses of immediate-release methylphenidate...
  99. ncbi Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension
    Ylva Ginsberg
    Department of Clinical Neuroscience, Division of Psychiatry and Center of Neurodevelopmental Disorders, Karolinska Institutet, Stockholm, Sweden
    Br J Psychiatry 200:68-73. 2012
    ..Attention-deficit hyperactivity disorder (ADHD) is highly prevalent in prison inmates, but pharmacological treatment has not yet been evaluated in this group...
  100. pmc Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance
    Alison Looby
    Department of Psychology, University at Albany, State University of New York, USA
    Exp Clin Psychopharmacol 19:433-44. 2011
    Nonmedical use of prescription-stimulant medication such as methylphenidate (MPH) has increased among college students over the past several years. Common motivations for use include enhancements in cognition and subjective arousal...
  101. ncbi Slowing of growth in height and weight on stimulants: a characteristic pattern
    A Poulton
    Department of Paediatrics, Nepean Hospital, Penrith, New South Wales, Australia
    J Paediatr Child Health 39:180-5. 2003
    ..The aims of the present study were to describe the growth pattern of children starting stimulant medication and to analyse the changes over time in height, weight and height velocity in a cohort of treated patients...

Research Grants72

  1. Validation of a functional MRI-based reward processing task as a non-invasive too
    MARY LOUISE PHILLIPS; Fiscal Year: 2010
    ..from animal studies and human neuroimaging studies involving pharmacological challenge with amphetamine and methylphenidate support the role of dopamine (DA) release in reward-related ventral striatal (VS) functioning...
  2. Dopamine Transporter Structure and Function
    Christopher K Surratt; Fiscal Year: 2010
    ..the DAT, as well as information on DAT recognition of drugs with less abuse potential such as benztropine and methylphenidate. Elucidating at the amino acid residue level the mechanisms of discriminating abused and non-abused ..
  3. smFRET Investigation of Gating in a Neurotransmitter Transporter Homolog
    RACHEL ANN KOLSTER; Fiscal Year: 2013
    ..includes the transporters for serotonin, dopamine, and norepinephrine, which are targeted by antidepressants, methylphenidate (Ritalin), and the widely abused psychostimulants cocaine and amphetamine...
  4. PCBs, PBDEs, Hearing Loss & Attention/Impulsivity: Mechanistic Studies in Animals
    Susan L Schantz; Fiscal Year: 2010
    ..Drug challenges with methylphenidate and amphetamine will determine if commonly prescribed ADHD pharmacotherapies improve the performance of PCB- ..
  5. Dopamine Transporter Cell Surface Dynamics
    Haley E Melikian; Fiscal Year: 2013
    ..and is the primary target for addictive and therapeutic psychostimulants, such as amphetamine, cocaine and methylphenidate (Ritalin) as well as for antidepressants, such as bupropion (Wellbutrin)...
  6. Neuroimaging and Behavioral Biomarkers for ADHD in Children
    Martin H Teicher; Fiscal Year: 2010
    ..only included boys aged 9 - 12 who met criteria for Combined Subtype, and had been previously treated with methylphenidate (MPH)...
  7. Dopamine Transporter Regulation by Endocytosis
    Alexander D Sorkin; Fiscal Year: 2013
    ..neurons and to determine how these dynamics are regulated by psychostimulant drugs of abuse such as cocaine, methylphenidate (MPH) and amphetamine (AMPH)...
  8. The rodent continuous performance task: Filling the vigilance translational gap
    JARED WILLIAM YOUNG; Fiscal Year: 2010
    ..predictive validity of the rCPT by determining whether psychostimulants such as nicotine, amphetamine, and methylphenidate will improve performance and whether ketamine will impair vigilance performance, consistent with human CPT ..
  9. Modeling Developmental Neurotoxicity of Pesticides in Zebrafish
    Lori A White; Fiscal Year: 2010
    ..DAT) levels, hyperactivity and impulsive-like behavior, amelioration of the behavioral deficits by methylphenidate (Ritalin), and a male gender-preference of these effects...
  10. Locus Coeruleus Function and Methylphenidate Action
    BARRY DALE WATERHOUSE; Fiscal Year: 2013
    ..project is to investigate interactions between the central noradrenergic system and systemically administered methylphenidate (MPH) - RitalinR in juvenile, adult and aged rats...
  11. The Role of Apathy in Glycemic Control
    Cyrus V Desouza; Fiscal Year: 2011
    ..Specific Aim 1: Evaluate if methylphenidate treatment of apathy improves glycemic control in patients with poorly controlled diabetes...
  12. Genetic Variants of Human Carboxylesterase 1 Influence the Activation and Antivir
    John S Markowitz; Fiscal Year: 2012
    ..Markedly altered pharmacokinetic and pharmacodynamic profiles of the hCES1 selective substrate methylphenidate have been observed in a human subject carrying the hCES1 variants, Gly143Glu and Asp260fs, during our ..
  13. DBH, D2High and Cocaine Paranoia/Aversion: A [11C]PHNO PET Study
    Robert T Malison; Fiscal Year: 2010
    ..D2 receptor (D2high), and 3) individual sensitivity to the subjectively aversive effects of psychostimulants (methylphenidate and/or cocaine)...
  14. Phosphorylation and Regulation of Dopamine Transporters
    Roxanne A Vaughan; Fiscal Year: 2010
    ....
  15. Endotoxin-induced inflammation affects striatal dopamine: A raclopride PET study
    Evan D Morris; Fiscal Year: 2013
    ..double-blind study, we will use positron emission tomography (PET) and [C-11]raclopride to measure methylphenidate-induced release of dopamine in the striatum in 10 healthy subjects...
  16. Non-Tropane Irreversible Dopamine Transporter Ligands
    DAVID JOHN LAPINSKY; Fiscal Year: 2010
    ..based irreversible ligands essential for labeling the DAT;and 2) Identify the structural elements of methylphenidate-based irreversible ligands for labeling the DAT...
  17. Neurobehavioral Impacts of Early Mn Exposures
    Donald R Smith; Fiscal Year: 2013
    ..resulting behavioral deficits by determining whether Mn exposure alters the dose- response relationship of methylphenidate (Ritalin), a dopamine transporter (DAT) inhibitor, and whether the drug alleviates behavioral deficits due to ..
  18. Preweanling Methylphenidate Exposure and Reward Behavior
    Cynthia Crawford; Fiscal Year: 2009
    ..for attention deficit hyperactivity disorder (ADHD) and the majority of these children are treated with methylphenidate (Ritalin)...
  19. Apathy in Alzheimer's Disease Methylphenidate Trial
    Paul B Rosenberg; Fiscal Year: 2010
    ..from a double blind, placebo controlled single-site crossover pilot study suggest that the dopamine agonist methylphenidate was superior to placebo for the treatment of apathy in AD (Lancttt, in press)...
  20. Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
    JAMES JOHN MCGOUGH; Fiscal Year: 2013
    ..First, all participants will have a 4-week open-label stimulant trial with dextro- methylphenidate extended release (d-MPH-XR) to determine an optimal dose...
  21. Comparative Safety and Effectiveness of Stimulants in Medicaid Youth with ADHD
    Almut G Winterstein; Fiscal Year: 2010
    ..2006 to: (1) evaluate the cardiac risk of stimulants overall, and of mixed amphetamine salts (MAS) versus methylphenidate (MPH) individually, on fatal or severe cardiovascular events;(2) assess whether stimulant risk is modified ..
  22. Developmental Mechanisms Underlying Risk Behaviors and Their Treatment
    Kai Christian Sonntag; Fiscal Year: 2013
    ..In Aim 2, we will determine effective doses (ED50s) of methylphenidate, atomoxetine, and guanficine on impulsivity at different ages and across sex...
  23. Structural and Mechanistic Characterization of Neurotransmitter Reuptake Inhibiti
    DANENG WANG; Fiscal Year: 2012
    ..and therefore are the primary targets for: antidepressants such as fluoxetine (Prozac), sertraline (Zoloft), methylphenidate (Ritalin) -a prescription drug commonly used to treat attention-deficit hyperactivity disorder (ADHD), and ..
  24. Improving Psychiatric Interventions at the End of Life
    Scott A Irwin; Fiscal Year: 2012
    ..Small studies and our pilot work have provided initial evidence for the safety and efficacy of methylphenidate for rapidly treating depression in hospice settings...
  25. Low-Dose Methylphenidate and the Prefrontal Cortex
    Craig W Berridge; Fiscal Year: 2013
    Low doses of psychostimulants, including methylphenidate (MPH/Ritalin), are widely used clinically due to their behavioral-calming and cognition-enhancing actions...
  26. How and Where Methylphenidate Exerts Effect in Adolescent and Adult Brains
    Nachum Dafny; Fiscal Year: 2013
    ..of the Journal of the American Academy of child and adolescent Psychiatry report the risks and benefits of methylphenidate (MPD) use in the treatment of attention deficit hyperactive disorder (ADHD) and strongly indicate the need of ..
  27. Bulimia nervosa and dopamine: a link to addictions?
    Allegra I Broft; Fiscal Year: 2012
    ..Patients and controls will undergo 2 PET scans with [11C]raclopride, pre/post pharmacological challenge with methylphenidate, for the measurement of striatal DA type 2 (D2) receptor binding potential (BP) and DA release...
  28. Methylphenidate, opioid receptors and addiction
    Jinmin Zhu; Fiscal Year: 2011
    ..provided by applicant): The long term goals of this project are to determine if oral therapeutic doses of methylphenidate are associated with increased risk of drug addiction...
  29. Drugs of Abuse and Memory Span
    JOSEPH MARK GALIZIO; Fiscal Year: 2012
    ..midazolam), NMDA antagonists (dizocilpine, ketamine), opiates (morphine), psychostimulants (methylphenidate, methamphetamine, MDMA), and an anticholinergic hallucinogen (scopolamine)...
  30. Alcohol Biomarkers In Post Liver Transplant Patients
    Michael F Fleming; Fiscal Year: 2013
    ..The second study tested the efficacy of methylphenidate in a sample 13 children with a diagnosis of Attention Deficit Disorder and Fetal Alcohol Spectrum Disorder...
  31. Translational and epigenetic profiling of cell types associated with addiction
    Nathaniel Heintz; Fiscal Year: 2010
    ..addiction;2) to collect translational profiles from each of these cell types in mice exposed to cocaine, methylphenidate, and methamphetamine 3) perform in depth comparative analysis of these resulting microarray datasets to ..
  32. Methylphenidate, Serotonin and Dopamine Interactions
    Sara R Jones; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The clinical use of methylphenidate (MPH, Ritalin) for treatment of attention-deficit/hyperactivity disorder is widespread, and there is a growing problem of MPH abuse, especially in college-age ..
  33. Methylphenidate Use to Improve Outcomes in Geriatric Depression
    Helen Lavretsky; Fiscal Year: 2012
    ..We hypothesized that the addition of methylphenidate (MPH) to the serotonergic drug, citalopram, may result in better clinical outcomes of the affective and ..
  34. Novel Ondansetron Formulation for Combination Treatment of Psychostimulant Abuse
    Ashwin A Patkar; Fiscal Year: 2010
    ..pharmacokinetic, safety and pharmacodynamic interactions with simultaneously-administered immediate-release methylphenidate;(3) a proof-of-concept phase II efficacy trial on a combination of immediate-release methylphenidate and Ond-..
  35. Neurobiology of the Cognition Enhancing Actions of Psychostimulants
    Robert C Spencer; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Psychostimulants, including methylphenidate (MPH), are currently the most effective treatment for attention-deficit hyperactivity disorder (ADHD)...
  36. Stimulants and Vascular Events in ADHD
    Mark Olfson; Fiscal Year: 2010
    ..for youth with attention-deficit/hyperactivity disorder (ADHD), mixed salts of amphetamine (MAS) and methylphenidate (MPH), may increase the risk of stroke, myocardial infarction, and other vascular events...
  37. Traumatic Brain Injury Clinical Trials Network
    Joseph H Ricker; Fiscal Year: 2010
    ..Special emphasis has been placed on the study of the effects of methylphenidate on executive functioning and outcome after TBI and the influence of gender and dopamine transporter genotype ..
  38. Fine Mapping Genes for Cocaine Locomotor Response in ENU Mutagenized Mice
    Lisa M Tarantino; Fiscal Year: 2010
    ..hyperlocomotion in a novel environment, an exaggerated locomotor response to the psychostimulants cocaine and methylphenidate and a prolonged release of corticosterone following an acute stressor...
  39. Neuroimaging of diet and medication in the treatment of ADHD
    Steven R Pliszka; Fiscal Year: 2013
    ..Phase II, (3 years), we will seek to determine the relative and combined efficacy of a restriction diet and methylphenidate in the treatment of ADHD, the acceptability/compliance of the diet to families and the child's ..
  40. Developmental Neuroendocrine Effects of PCBs and PBDEs: Parallels with ADHD
    RICHARD FIELD SEEGAL; Fiscal Year: 2010
    ..reductions in central catecholamines can be ameliorated following either maternal T4 supplementation or adult methylphenidate exposure and (iv) the effects of these manipulations on mRNA expression and proteins that regulate ..
  41. Drug Transporters and the Disposition of ADHD Therapeutic Agents
    John S Markowitz; Fiscal Year: 2010
    ..Medications include the psychostimulants (STIMs), methylphenidate (MPH) and amphetamine (AMP), and newer non-STIMs atomoxetine (ATM) and modafinil (MDF)...
  42. Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence
    FRANCIS JOSEPH MCCLERNON; Fiscal Year: 2013
    ..the following conditions: 1) smoking as usual, 2) 24 hr smoking abstinence, and 3) 24 hr smoking abstinence + methylphenidate (MPH)...
  43. ADHD Therapeutic: PD2005 DA Transport Inhibitor
    Frank Zemlan; Fiscal Year: 2012
    ..The American Academy of Pediatrics identifies the non-selective DA transport inhibitors methylphenidate and amphetamine as the only approved first-line treatments for ADHD...
  44. Neural Circuits Underlying Adaptive Behavior and Addiction
    GERO MIESENBOECK; Fiscal Year: 2013
    ..The effect of cocaine, methylphenidate, and amphetamine on this learning process will be determined, revealing the effects of these drugs of abuse ..
  45. Methylphenidate, vigilance, and visual perception
    Kara L Agster; Fiscal Year: 2010
    ..Amphetamine-like stimulants, such as methylphenidate (MPH, Ritalin), are the primary treatments for ADHD...
  46. Pharmacological Dissociation of Control Circuits in ADHD and Alcohol Dependence
    Chandra Sekhar Sripada; Fiscal Year: 2013
    ..controls and adults with ADHD, alcohol dependence, and ADHD comorbid with alcohol dependence in response to methylphenidate, naltrexone, and placebo challenge...
  47. Psychostimulants induce long-term changes in nociception.
    Michael M Morgan; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Psychostimulants, such as methylphenidate (MPH) and methamphetamine, are widely used and abused. The short-term adverse health effects of methamphetamine abuse are well known...
  48. Career Development Award
    ANNETTE FLECKENSTEIN; Fiscal Year: 2013
    ..formation is associated with, and may contribute to, the dopaminergic deficits caused by the stimulant;2) methylphenidate uniquely affects monoaminergic vesicular function and distribution by a mechanism that includes novel shifts ..
  49. PET Studies of Amphetamine Treatment of ADHD
    George A Ricaurte; Fiscal Year: 2013
    ..who have never received pharmacological treatment for ADHD;2) Adults with ADHD who have been treated with methylphenidate, which is known to lack DA neurotoxic potential;and 3) Age- and gender- matched healthy adults never treated ..
  50. Risk of cocaine addiction after methylphenidate plus SSRI combination treatment
    Michela Marinelli; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Exposure to methylphenidate (a dopamine reuptake inhibitor) mimics several behavioral and molecular effects of cocaine...
  51. Sustained-Release Methylphenidate For Management of Methamphetamine Use Disorders
    WALTER NMN LING; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): This four-year study will evaluate the efficacy of treatment with methylphenidate compared to placebo in the context of behavioral therapy for methamphetamine use disorders (abuse or dependence) in a ..
  52. Efficacy of an Expectancy Challenge to Reduce Non-Prescribed Use of Stimulant Med
    ALLISON LABBE; Fiscal Year: 2012
    ..provided by applicant): Non-prescribed use of stimulant medications among college students, such as methylphenidate (Ritalin(R)) and amphetamine (Adderall(R)), has become a public health concern...
  53. Patterns of Drug Use and Abuse in the Brazilian Rave Culture
    James Inciardi; Fiscal Year: 2009
    ..ecstasy), GHB, ketamine, LSD, methamphetamine, and a few prescription drugs, such as dextroamphetamine and methylphenidate. Recently, reports in both popular and scientific media have begun to indicate that ecstasy use is increasing ..
  54. Impulsivity and Stimulant Response in Early- and Late-Onset CD with Comorbid ADHD
    Charles W Mathias; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The purpose of this study is to determine the dose-response effects of methylphenidate treatment on laboratory-measured impulsive behavior of two groups of adolescents, those with either childhood- ..
  55. Extended-Release Mixed Amphetamine Salts for Adults ADHD and Cocaine Dependence
    JOHN G GRABOWSKI; Fiscal Year: 2012
    ..To date studies of immediate and sustained-release methylphenidate for adult cocaine-dependent individuals with ADHD have produced mixed results, suggesting that high doses of ..
  56. Functional Neuroimaging of Attention in Autism
    BENJAMIN YERYS; Fiscal Year: 2012
    ..from Attention Deficit/Hyperactivity Disorder (ADHD), but this approach has shown reduced efficacy of methylphenidate (i.e., ritalin) treatment in children with ASD...
  57. Smoking/Nicotine Dependence in Attention Deficit Hyperactivity Disorder (ADHD)
    Scott H Kollins; Fiscal Year: 2012
    ..These studies include: 1) an existing human laboratory study of the abuse liability of methylphenidate in adults with and without ADHD (R01DA017196);2) an existing candidate gene study of persistent ADHD (..
  58. The prefrontal cortex in salience and control in cocaine addiction: phFMRI study
    Rita Z Goldstein; Fiscal Year: 2012
    ..We will compare these fMRI results with and without oral methylphenidate (MPH), a dopamine agonist, used here to enhance the salience of the drug-related cues (Aim 2)...
  59. Neurobiological Mechanisms of Treatment Response in Geriatric Depression
    Helen Lavretsky; Fiscal Year: 2013
    ..emission tomography (PET) that is relevant to her ongoing investigation of the dopaminergic mechanisms of methylphenidate in geriatric depression;(2) extend her knowledge and skills to the use of functional MRI (fMRI) with the ..
  60. Extended Release Mixed Amphetamine Salts for Adult ADHD and Cocaine Dependence
    Frances Rudnick Levin; Fiscal Year: 2010
    ..To date studies of immediate and sustained-release methylphenidate for adult cocaine-dependent individuals with ADHD have produced mixed results, suggesting that high doses of ..
  61. Early Exposure to Stimulants as a Risk Factor for Substance Abuse
    Linda J Porrino; Fiscal Year: 2010
    ..Most of the studies conducted in children and adults with ADHD have suggested that medication with methylphenidate or amphetamine has either no effect or can be protectivefrom substance abuse disorders...
  62. COGNITIVE ASPECTS OF ADDICTION-RELATED BEHAVIOR
    Kathleen M Kantak; Fiscal Year: 2013
    ..the prefrontal cortex during adolescence that is prevented by treatment with either the stimulant medication methylphenidate or the non-stimulant medication atomoxetine;2) augmented vulnerability to cocaine addiction during adulthood ..
  63. Psychostimulants and Monoamine Transporters
    ANNETTE FLECKENSTEIN; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Methylphenidate (MPD) is a plasmalemmal dopamine (DA) transporter (DAT) inhibitor used to treat attention deficit hyperactivity disorder...
  64. Monoamine Transporter Structure-Function Studies
    CHRISTOPHER SURRATT; Fiscal Year: 2007
    ..g., dopamine, serotonin, various amphetamines) and inhibitor (e.g., cocaine, methylphenidate) recognition...
  65. NEUROCHEMICAL BASIS OF SLEEP HOMEOSTASIS
    William Dement; Fiscal Year: 2001
    ..Waking from stimulants (methamphetamine and methylphenidate) also induce CSR...
  66. Role of astroglia in cocaine-induced neurotoxicity
    Helene Benveniste; Fiscal Year: 2009
    ..Ca++]i following intravenous administration of cocaine and the local anesthetic lidocaine but not with methylphenidate indicating that cocaine's local anesthetic properties but not its catecholaminergic actions underlie ..
  67. HYPERKINETIC BOYS AND THEIR SIBLINGS AS YOUNG ADULTS
    Jan Loney; Fiscal Year: 1991
    ..The samples include: a) an Early Medicated group (referred between 1967-1972 and methylphenidate); b) a Transitional Medicated group (referred between 1972-1975 and treated primarily with methylphenidate); ..
  68. Methylphenidate and Binge Eating Disorder in Obese Humans
    Jennifer Nasser; Fiscal Year: 2009
    ..We propose to evaluate the effect of central dopamine manipulation (using methylphenidate, a drug that increases brain dopamine signaling) on binge eating behavior in obese women measured by food ..
  69. ACUPUNCTURE POINT TREATMENT FOR ADHA
    NEIL SONENKLAR; Fiscal Year: 1993
    ..It will investigate the effects of acupuncture point therapy, methylphenidate, placebo and the two active treatments combined...
  70. MEDICATED & UNMEDICATED ADHD BOYS AT MIDLIFE (35 TO 45)
    Jan Loney; Fiscal Year: 2005
    ..four groups: (1) 164 probands who were medicated as children with a central nervous system stimulant such as methylphenidate for an average of 3 years (the MED group), (2) 50 probands who were never medicated (UNMED), (3) 75 ..
  71. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2005
    ..Rationales for combination with methylphenidate (MPH) are that it may be synergistic, may extend the stimulant effect, and/or that CLON may address certain ..
  72. Transcriptomic Analysis of Therapeutics in Brain Trauma
    C Dixon; Fiscal Year: 2005
    ..our experimental model of TBI, and found three to be beneficial: amantadine hydroehloride, bromoeriptine, and methylphenidate. While all are putative dopaminergic agonists, they have varying degrees of specificity to DA systems...